Enpr-EMA priority activities

The aim of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) is to facilitate studies in order to increase the availability of medicines for children. It works by holding annual workshops to define priority tasks and setting up working groups to carry out specific activities. 

These highlighted activities include priority working areas of Enpr-EMA and its working groups. For more details and regular updates on Enpr-EMA activities, see also Enpr-EMA's regular newsletters.

Paediatric clinical trial preparedness

Enpr-EMA has published a draft framework about paediatric clinical trial preparedness, with recommendations for sponsors, principal investigators and trialists:

Trial preparedness, in this context, means a structured assessment of contributing factors that enable the smooth conduct of clinical trials in a timely manner, integrating information from multiple stakeholders.

Enpr-EMA held a two-month public consultation on the draft framework until 15 November 2019, with the aim of identifying potential gaps and presenting a more comprehensive view.

Enpr-EMA will publish an updated version of the framework, taking into account feedback recieved during the public consultation.

Involving young people and families

Involving young people and family members in clinical research has many benefits, including greater understanding of young people's perspectives and improvements in study design and the quality of clinical research.

Enpr-EMA has established young person advisory groups (YPAG) within the Enpr-EMA members. These members set up the European network of young people advisory groups (eYPAGnet), which aims to become the single point of contact for all YPAGs in Europe.

In 2017, in collaboration with Enpr-EMA, EMA has agreed on principles for involving patients and consumers below 18 years of age in the activities of its scientific committees and working parties:

This follows a 2014 Enpr-EMA survey with EMA's Paediatric Committee (PDCO) on the potential involvement of young people and families in PDCO activities and strengthening the participation of members representing patients' organisations in the Committee. For full details, see:

Enpr-EMA also surveyed its paediatric research networks on the involvement of young people and family members in 2012. The survey results indicated that, although more than half of the networks that responded actively involve young people or families, only three networks out of thirty-nine had developed strategies or guidelines for the involvement of young people and families. For these documents, see:

Collaboration with ethics committees

As of 2017, Enpr-EMA and the European Network of Research Ethics Committees (EUREC) are exploring ways of collaboration.

As a first step, Enpr-EMA and EUREC will collect ideas for collaboration and collect a survey on needs and expectations among their members.

Collaboration with paediatric research nurses

The role of research nurses in coordinating clinical trials involving children has become more important in recent years, due to increasing complexities of clinical trial design.

Enpr-EMA is exploring ways to facilitate connections between paediatric research nurse networks and groups in Europe. As a first step, it has compiled a list of networks and groups via the Enpr-EMA network:

Enpr-EMA has also carried out a survey with research nurses to investigate the training needs of research nurses involved in paediatric trials across Europe and to compare roles across specialties and countries. The survey results were published in 2017:

Informed consent requirements for paediatric clinical trials

Consent requirements are not harmonised in Europe and vary according to national laws and regulations. These discrepancies can present challenges for paediatric clinical trials, especially as many are conducted as multinational trials.

To provide a comprehensive multinational overview on informed consent and assent requirements of paediatric clinical trials across Europe, an Enpr-EMA working group has collated the legal requirements in EU Member States, plus Iceland and Norway: 

Enpr-EMA updates this document as necessary. 

For more information on the working group's findings, see:

Facilitating interactions between the pharmaceutical industry and networks

Enpr-EMA aims to facilitate interactions between medicine developers and paediatric research networks on issues related to paediatric medicine development. 

In 2018, Enpr-EMA published PDF iconguidance to pharmaceutical industry stakeholders outlining the recommended model for consulting paediatric research networks, particularly on developing and conducting paediatric investigation plans.

This guidance was informed by a 2015 Enpr-EMA survey with industry representatives and paediatric clinical trial networks on how they engage with one another. Enpr-EMA published the survey results in 2016: 

Enpr-EMA also facilitates interactions between SMEs and academic investigators in paediatric-medicine research, by providing them information on networking and partnership opportunities.

International collaboration

Enpr-EMA works with international partners specialising in the regulation of medicines for children, including with the:

Enpr-EMA has set up a working group to explore further collaborative opportunities with international regulators and paediatric research networks.

Input on public consultations

Enpr-EMA contributes to important public consultations related to paediatric medicine research in Europe. It publishes some of the comments it submits to public consultations on this website.

How useful was this page?

Add your rating